Optical Genome Mapping Enables Constitutional Chromosomal Aberration Detection
By LabMedica International staff writers Posted on 20 Jul 2021 |
Image: The Bionano Genomics Saphyr instrument used for Optical Genome Mapping (Photo courtesy of Bionano Genomics)
Optical genome mapping (OGM) is a novel method that fills this void by being able to detect all classes of structural variations (SVs), including copy number variations (CNVs). OGM is being adopted by laboratories as a tool for both postnatal constitutional genetic disorders and hematological malignancies.
A predisposition to tumor development is associated with some constitutional chromosomal abnormalities. Constitutional chromosome rearrangements are inherited from a carrier parent or occur de novo in the gametes and are present in all tissues. Acquired chromosome rearrangements occur during life and are limited to a specific tissue.
An international team of medical geneticists led by the Radboud University Medical Center (Nijmegen, the Netherlands) investigated the ability of optical genome mapping (OGM) to detect known constitutional chromosomal aberrations. Ultra-high-molecular-weight DNA was isolated from 85 blood or cultured cells and processed via OGM. A de novo genome assembly was performed followed by structural variant and CNV calling and annotation, and results were compared to known aberrations from standard-of-care tests such as karyotype, fluorescence in situ hybridization (FISH), and/or copy number variants (CNV) microarray). The team isolated ultra-high molecular weight DNA from the samples and preparing the samples for OGM with the Bionano Genomics Saphyr instruments (San Diego, CA, USA).
The scientists analyzed 99 chromosomal aberrations, including seven aneuploidies, 19 deletions, 20 duplications, 34 translocations, six inversions, two insertions, six isochromosomes, one ring chromosome, and four complex rearrangements. Several of these variants encompass complex regions of the human genome involved in repeat-mediated microdeletion/microduplication syndromes. High-resolution OGM reached 100% concordance compared to standard assays for all aberrations with non-centromeric breakpoints. This proof-of-principle study demonstrates the ability of OGM to detect nearly all types of chromosomal aberrations.
In a related paper, members of the same team assessed OGM in the hematological malignancy setting, retrospectively using the optical mapping with the Saphyr genome imaging system to search for informative chromosomal changes in 52 hematological malignancy samples from cases diagnosed in the past.
The authors concluded that their results highlight the potential for OGM to provide a cost-effective and easy-to-use alternative that would allow comprehensive detection of chromosomal aberrations and structural variants, which could give rise to an era of “next-generation cytogenetics. The study was published on July 7, 2021 in the American Journal of Human Genetics.
Related Links:
Radboud University Medical Center
Bionano Genomics
A predisposition to tumor development is associated with some constitutional chromosomal abnormalities. Constitutional chromosome rearrangements are inherited from a carrier parent or occur de novo in the gametes and are present in all tissues. Acquired chromosome rearrangements occur during life and are limited to a specific tissue.
An international team of medical geneticists led by the Radboud University Medical Center (Nijmegen, the Netherlands) investigated the ability of optical genome mapping (OGM) to detect known constitutional chromosomal aberrations. Ultra-high-molecular-weight DNA was isolated from 85 blood or cultured cells and processed via OGM. A de novo genome assembly was performed followed by structural variant and CNV calling and annotation, and results were compared to known aberrations from standard-of-care tests such as karyotype, fluorescence in situ hybridization (FISH), and/or copy number variants (CNV) microarray). The team isolated ultra-high molecular weight DNA from the samples and preparing the samples for OGM with the Bionano Genomics Saphyr instruments (San Diego, CA, USA).
The scientists analyzed 99 chromosomal aberrations, including seven aneuploidies, 19 deletions, 20 duplications, 34 translocations, six inversions, two insertions, six isochromosomes, one ring chromosome, and four complex rearrangements. Several of these variants encompass complex regions of the human genome involved in repeat-mediated microdeletion/microduplication syndromes. High-resolution OGM reached 100% concordance compared to standard assays for all aberrations with non-centromeric breakpoints. This proof-of-principle study demonstrates the ability of OGM to detect nearly all types of chromosomal aberrations.
In a related paper, members of the same team assessed OGM in the hematological malignancy setting, retrospectively using the optical mapping with the Saphyr genome imaging system to search for informative chromosomal changes in 52 hematological malignancy samples from cases diagnosed in the past.
The authors concluded that their results highlight the potential for OGM to provide a cost-effective and easy-to-use alternative that would allow comprehensive detection of chromosomal aberrations and structural variants, which could give rise to an era of “next-generation cytogenetics. The study was published on July 7, 2021 in the American Journal of Human Genetics.
Related Links:
Radboud University Medical Center
Bionano Genomics
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access